Oligonucleotide CDMO Market - Global Forecast to 2029
商品番号 : SMB-72152
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 255 |
| 図表数 | 326 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs.
世界のオリゴヌクレオチドCDMO市場は、2024年の25億1,000万米ドルから2029年には67億3,000万米ドルに達すると予測されており、予測期間中のCAGRは21.8%です。市場の成長を促進する主な要因には、新規のオリゴベースの医薬品の発売への注目の高まりと、CDMOへのアウトソーシングの増加が含まれます。
Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.
アンチセンスオリゴヌクレオチド (ASO)、低分子干渉 RNA (siRNA)、アプタマーなどのオリゴヌクレオチドは、これらの薬剤がもたらす特異性と標的作用により注目されています。これにより、開発活動が増加し、その後 FDA の承認が得られました。たとえば、2023 年 4 月、Qalsody (tofersen) は、スーパーオキシド ジスムターゼ 1 (SOD1) 遺伝子の変異に関連する筋萎縮性側索硬化症 (ALS) の治療薬として米国 FDA によって承認されました。さらに、臨床開発と製造（臨床および商業）をアウトソーシングする際に発生する専門知識とコストの削減が、この市場の成長をさらに支えています。
“The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023”
In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.
“The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period”
Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.
“Asia Pacific: The fastest growing region in the oligonucleotide CDMO market”
Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Supply Side – 65% and Demand Side – 35%
- By Designation: (Managers) – 45%, (CXOs, Directors)- 30%, and(Executives) – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa – 5%
List of Companies Profiled in the Report:
- Bachem (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Maravai Lifesciences (US)
- GenScript (US)
- Wuxi Apptec (China)
- Eurofins Scientific (Luxembourg)
- Lonza (Switzerland)
- Danaher Corporation (US)
- Syngene International Limited (US)
- EUROAPI (France)
- Ajinomoto Co., Inc. (Japan)
- ST Pharm (South Korea)
- Kaneka Corporation (Japan)
- Aurigene Pharmaceutical Services Ltd. (India)
- PolyPeptide Group (Switzerland)
- Biospring (Germany)
- Oligo factory (US)
- Corden Pharma (Switzerland)
- LGC Biosearch Technologies (UK)
- Bio-Synthesis Inc (US)
- Microsynth (Switzerland)
- Synoligo Biotechnologies, Inc. (US)
- Hongene Biotech Corporation (China)
- Sylentis, S.A. (Spain)
- Creative Biogene. (US)
Research Coverage:
This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing ), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
- Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
- Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide CDMO market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED & REGIONS CONSIDERED 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 33
2.2 MARKET ESTIMATION METHODOLOGY 34
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 37
2.2.2 TOP-DOWN APPROACH 37
2.3 MARKET GROWTH RATE PROJECTIONS 38
2.4 DATA TRIANGULATION 40
2.5 RESEARCH ASSUMPTIONS 41
2.6 RESEARCH LIMITATIONS 41
2.7 RISK ANALYSIS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW 47
4.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE & COUNTRY (2023) 48
4.3 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS 2029 48
4.4 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS 2029 49
4.5 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY END USER, 2023 49
4.6 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Growing focus on development and commercialization of oligo-based therapeutics 52
5.2.1.2 Advantages of contract development and manufacturing 54
5.2.1.3 Increasing focus on precision/personalized medicine 54
5.2.1.4 Technological advancements 54
5.2.2 RESTRAINTS 55
5.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications 56
5.2.4 CHALLENGES 56
5.2.4.1 Lack of sustainable and eco-friendly supply chain 56
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 57
5.4 SUPPLY CHAIN ANALYSIS 57
5.5 VALUE CHAIN ANALYSIS 58
5.6 ECOSYSTEM ANALYSIS 60
5.6.1 ROLE IN ECOSYSTEM 60
5.7 TECHNOLOGY ANALYSIS 62
5.7.1 KEY TECHNOLOGIES 62
5.7.1.1 Process technologies 62
5.7.1.1.1 Solid-phase synthesis 62
5.7.1.1.2 Liquid-phase synthesis 62
5.7.1.1.3 Enzymatic oligo synthesis 63
5.7.2 COMPLEMENTARY TECHNOLOGIES 64
5.7.2.1 Purification, analysis, and quality control technologies 64
5.7.2.1.1 Chromatography 64
5.7.2.1.2 Mass spectrometry 64
5.7.2.2 Other technologies 64
5.7.2.2.1 Polymerase chain reaction (PCR) 64
5.7.2.2.2 Next-generation sequencing 65
5.7.3 ADJACENT TECHNOLOGIES 65
5.7.3.1 3D printing 65
5.8 PRICING ANALYSIS 66
5.8.1 INDICATIVE PRICE OF OLIGONUCLEOTIDE CDMO SERVICES, BY KEY PLAYER 66
5.8.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE) 67
5.9 KEY CONFERENCES & EVENTS IN 2024–2025 67
5.10 REGULATORY LANDSCAPE 68
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
5.10.2 REGULATORY FRAMEWORK 71
5.11 PORTER’S FIVE FORCES ANALYSIS 72
5.11.1 DEGREE OF COMPETITION 73
5.11.2 BARGAINING POWER OF SUPPLIERS 73
5.11.3 BARGAINING POWER OF BUYERS 73
5.11.4 THREAT OF SUBSTITUTES 73
5.11.5 THREAT OF NEW ENTRANTS 73
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 74
5.12.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE CDMO SERVICES 74
5.13 KEY BUYING CRITERIA 75
5.14 INVESTMENT & FUNDING SCENARIO 76
5.15 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 77
6 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE 79
6.1 INTRODUCTION 80
6.2 CONTRACT MANUFACTURING 80
6.2.1 COMMERCIAL STAGE 83
6.2.1.1 Flexible, scalable production facilities to propel market growth 83
6.2.2 CLINICAL STAGE 85
6.2.2.1 Growing demand for oligonucleotide-based therapeutics to drive market 85
6.3 CONTRACT DEVELOPMENT 88
6.3.1 GROWING FOCUS ON REDUCING MANUFACTURING RISKS TO SUPPORT MARKET GROWTH 88
6.4 OTHER SERVICES 90
7 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE 93
7.1 INTRODUCTION 94
7.2 ANTISENSE OLIGONUCLEOTIDES 94
7.2.1 SPECIFIC DEVELOPMENT & MANUFACTURING REQUIREMENTS WELL-SUPPORTED BY CDMOS TO DRIVE MARKET GROWTH 94
7.3 SMALL INTERFERING RNA 96
7.3.1 POTENTIAL IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH 96
7.4 OTHER OLIGONUCLEOTIDES 99
8 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION 102
8.1 INTRODUCTION 103
8.2 THERAPEUTIC APPLICATIONS 103
8.2.1 GROWING DEMAND FOR OLIGONUCLEOTIDE-BASED THERAPEUTICS TO DRIVE MARKET GROWTH 103
8.3 RESEARCH APPLICATIONS 105
8.3.1 USE OF OLIGOS IN SEQUENCING FOR ADVANCING DRUG DEVELOPMENT TO SUPPORT GROWTH 105
8.4 DIAGNOSTIC APPLICATIONS 108
8.4.1 GROWING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND IVD TO PROPEL MARKET 108
9 OLIGONUCLEOTIDE CDMO MARKET, BY END USER 111
9.1 INTRODUCTION 112
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 112
9.2.1 INCREASED INVESTMENTS IN OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT MARKET GROWTH 112
9.3 DIAGNOSTIC COMPANIES 114
9.3.1 GROWTH OF PERSONALIZED DIAGNOSTICS TO PROPEL MARKET 114
9.4 OTHER END USERS 117
10 OLIGONUCLEOTIDE CDMO MARKET, BY REGION 120
10.1 INTRODUCTION 121
10.2 NORTH AMERICA 121
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 121
10.2.2 US 126
10.2.2.1 Rising approvals of oligonucleotide-based drugs to support market growth 126
10.2.3 CANADA 128
10.2.3.1 Government initiatives to drive market growth in Canada 128
10.3 EUROPE 130
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130
10.3.2 GERMANY 133
10.3.2.1 Academic-industry collaborations to drive market 133
10.3.3 UK 136
10.3.3.1 Strategic investments in biomanufacturing to boost market growth 136
10.3.4 FRANCE 138
10.3.4.1 Focus on advanced biologics manufacturing to drive market 138
10.3.5 ITALY 140
10.3.5.1 Increasing focus on biotechnology innovation to boost market growth 140
10.3.6 SPAIN 142
10.3.6.1 Strategic investments in biotechnology to support market growth 142
10.3.7 REST OF EUROPE 144
10.4 ASIA PACIFIC 146
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 147
10.4.2 CHINA 151
10.4.2.1 Government-backed Initiatives and expansion of major companies to strengthen biotechnology sector in China 151
10.4.3 JAPAN 153
10.4.3.1 Increased investment in oligonucleotide research and manufacturing to boost market 153
10.4.4 INDIA 155
10.4.4.1 Rapidly expanding biopharma ecosystem to drive market 155
10.4.5 SOUTH KOREA 158
10.4.5.1 Robust government support to expand oligonucleotide CDMO sector 158
10.4.6 REST OF ASIA PACIFIC 160
10.5 LATIN AMERICA 162
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 163
10.5.2 BRAZIL 165
10.5.2.1 Strong research institutions and growing collaboration between academia and industry to support market growth 165
10.5.3 MEXICO 167
10.5.3.1 Rapidly advancing pharmaceutical and biotechnology sectors to fuel growth 167
10.5.4 REST OF LATIN AMERICA 169
10.6 MIDDLE EAST & AFRICA 171
10.6.1 RISING INVESTMENTS IN HEALTHCARE AND GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET 171
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 172
10.6.3 MACROECONOMIC OUTLOOK FOR AFRICA 172
11 COMPETITIVE LANDSCAPE 175
11.1 OVERVIEW 175
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 175
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET 176
11.3 REVENUE ANALYSIS, 2021–2023 177
11.4 MARKET SHARE ANALYSIS, 2023 178
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 180
11.5.1 STARS 180
11.5.2 EMERGING LEADERS 180
11.5.3 PERVASIVE PLAYERS 181
11.5.4 PARTICIPANTS 181
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 182
11.5.5.1 Company footprint 182
11.5.5.2 Region footprint 183
11.5.5.3 Service type footprint 184
11.5.5.4 Type footprint 185
11.5.5.5 Application footprint 186
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 187
11.6.1 PROGRESSIVE COMPANIES 187
11.6.2 RESPONSIVE COMPANIES 187
11.6.3 DYNAMIC COMPANIES 187
11.6.4 STARTING BLOCKS 187
11.6.5 COMPETITIVE BENCHMARKING 189
11.6.5.1 Detailed list of key startups/SMES 189
11.6.5.2 Competitive benchmarking of startups/SMEs 190
11.7 COMPANY VALUATION AND FINANCIAL METRICS 191
11.8 BRAND/SERVICE COMPARISON 192
11.9 COMPETITIVE SCENARIO 193
11.9.1 DEALS 193
11.9.2 EXPANSIONS 194
12 COMPANY PROFILES 196
12.1 KEY PLAYERS 196
12.1.1 BACHEM 196
12.1.1.1 Business overview 196
12.1.1.2 Services offered 197
12.1.1.3 Recent developments 198
12.1.1.3.1 Deals 198
12.1.1.4 MnM view 198
12.1.1.4.1 Key strengths 198
12.1.1.4.2 Strategic choices 198
12.1.1.4.3 Weaknesses and competitive threats 198
12.1.2 THERMO FISHER SCIENTIFIC INC. 199
12.1.2.1 Business overview 199
12.1.2.2 Services offered 200
12.1.2.3 Recent developments 201
12.1.2.3.1 Deals 201
12.1.2.3.2 Expansions 201
12.1.2.4 MnM view 201
12.1.2.4.1 Key strengths 201
12.1.2.4.2 Strategic choices 201
12.1.2.4.3 Weaknesses and competitive threats 202
12.1.3 AGILENT TECHNOLOGIES, INC. 203
12.1.3.1 Business overview 203
12.1.3.2 Services offered 204
12.1.3.3 Recent developments 205
12.1.3.3.1 Deals 205
12.1.3.3.2 Expansions 205
12.1.3.4 MnM view 206
12.1.3.4.1 Key strengths 206
12.1.3.4.2 Strategic choices 206
12.1.3.4.3 Weaknesses and competitive threats 206
12.1.4 WUXI APPTEC 207
12.1.4.1 Business overview 207
12.1.4.2 Services offered 208
12.1.4.3 Recent developments 209
12.1.4.3.1 Expansions 209
12.1.4.4 MnM view 209
12.1.4.4.1 Key strengths 209
12.1.4.4.2 Strategic choices made 209
12.1.4.4.3 Weaknesses and competitive threats 210
12.1.5 MARAVAI LIFESCIENCES 211
12.1.5.1 Business overview 211
12.1.5.2 Services offered 212
12.1.5.3 Recent developments 213
12.1.5.3.1 Deals 213
12.1.6 LONZA 214
12.1.6.1 Business overview 214
12.1.6.2 Services offered 215
12.1.6.3 Recent developments 216
12.1.6.3.1 Deals 216
12.1.6.3.2 Expansions 216
12.1.7 EUROFINS SCIENTIFIC 217
12.1.7.1 Business overview 217
12.1.7.2 Services offered 218
12.1.7.3 Recent developments 219
12.1.7.3.1 Deals 219
12.1.7.3.2 Expansions 219
12.1.8 DANAHER CORPORATION 220
12.1.8.1 Business overview 220
12.1.8.2 Services offered 222
12.1.8.3 Recent developments 222
12.1.8.3.1 Expansions 222
12.1.9 GENSCRIPT 223
12.1.9.1 Business overview 223
12.1.9.2 Services offered 224
12.1.9.3 Recent developments 225
12.1.9.3.1 Expansions 225
12.1.10 SYNGENE INTERNATIONAL LIMITED 226
12.1.10.1 Business overview 226
12.1.10.2 Services offered 227
12.1.10.3 Recent developments 227
12.1.10.3.1 Expansions 227
12.1.11 EUROAPI 228
12.1.11.1 Business overview 228
12.1.11.2 Services offered 229
12.1.11.3 Recent developments 230
12.1.11.3.1 Deals 230
12.1.11.3.2 Expansions 230
12.1.12 AJINOMOTO CO., INC. 231
12.1.12.1 Business overview 231
12.1.12.2 Services offered 232
12.1.13 ST PHARM 233
12.1.13.1 Business overview 233
12.1.13.2 Services offered 234
12.1.13.3 Recent developments 234
12.1.13.3.1 Expansions 234
12.1.13.3.2 Other developments 234
12.1.14 KANEKA CORPORATION 235
12.1.14.1 Business overview 235
12.1.14.2 Services offered 236
12.1.15 POLYPEPTIDE GROUP 237
12.1.15.1 Business overview 237
12.1.15.2 Services offered 238
12.1.15.3 Recent developments 239
12.1.15.3.1 Deals 239
12.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD. 240
12.1.16.1 Business overview 240
12.1.16.2 Services offered 240
12.1.17 BIOSPRING 241
12.1.17.1 Business overview 241
12.1.17.2 Services offered 241
12.1.17.3 Recent developments 242
12.1.17.3.1 Service approvals 242
12.1.17.3.2 Expansions 242
12.2 OTHER PLAYERS 243
12.2.1 OLIGO FACTORY 243
12.2.2 CORDEN PHARMA 243
12.2.3 LGC BIOSEARCH TECHNOLOGIES 244
12.2.4 BI0-SYNTHESIS, INC. 244
12.2.5 MICROSYNTH 245
12.2.6 SYNOLIGO BIOTECHNOLOGIES, INC. 245
12.2.7 HONGENE BIOTECH CORPORATION 246
12.2.8 SYLENTIS, S.A. 246
12.2.9 CREATIVE BIOGENE 247
13 APPENDIX 248
13.1 DISCUSSION GUIDE 248
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 251
13.3 CUSTOMIZATION OPTIONS 253
13.4 RELATED REPORTS 253
13.5 AUTHOR DETAILS 254
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 39
TABLE 2 OLIGONUCLEOTIDE CDMO MARKET: RISK ASSESSMENT ANALYSIS 42
TABLE 3 OLIGONUCLEOTIDE CDMO MARKET: IMPACT ANALYSIS 52
TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016–2023) 53
TABLE 5 INDICATIVE PRICE OF OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES, BY KEY PLAYER 66
TABLE 6 OLIGONUCLEOTIDE CDMO MARKET: LIST OF CONFERENCES & EVENTS 67
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 12 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES ANALYSIS 72
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF OLIGONUCLEOTIDE CDMO SERVICES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 74
TABLE 14 BUYING CRITERIA FOR OLIGONUCLEOTIDE CDMO MARKET, BY END USER 75
TABLE 15 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 80
TABLE 16 OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY STAGE, 2022–2029 (USD MILLION) 81
TABLE 17 OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 81
TABLE 18 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 82
TABLE 19 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 82
TABLE 20 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 82
TABLE 21 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 83
TABLE 22 COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY REGION, 2022–2029 (USD MILLION) 84
TABLE 23 NORTH AMERICA: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 84
TABLE 24 EUROPE: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 84
TABLE 25 ASIA PACIFIC: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 85
TABLE 26 LATIN AMERICA: COMMERCIAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 85
TABLE 27 CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY REGION, 2022–2029 (USD MILLION) 86
TABLE 28 NORTH AMERICA: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 87
TABLE 29 EUROPE: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 87
TABLE 30 ASIA PACIFIC: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 87
TABLE 31 LATIN AMERICA: CLINICAL-STAGE OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 88
TABLE 32 OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 89
TABLE 33 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 34 EUROPE: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 35 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 36 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 37 OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY REGION,
2022–2029 (USD MILLION) 91
TABLE 38 NORTH AMERICA: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 39 EUROPE: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 40 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 41 LATIN AMERICA: OTHER OLIGONUCLEOTIDE CDMO SERVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 42 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 94
TABLE 43 OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES,
BY REGION, 2022–2029 (USD MILLION) 95
TABLE 44 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 45 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 46 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 47 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 48 OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION,
2022–2029 (USD MILLION) 97
TABLE 49 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 50 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 51 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 52 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 53 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 54 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 55 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES,
BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 56 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 57 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER OLIGONUCLEOTIDES, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 58 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 103
TABLE 59 OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 60 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 61 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 62 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 63 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 64 OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 65 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 66 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 67 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 68 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 69 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 70 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 71 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 72 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 73 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 74 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022–2029 (USD MILLION) 112
TABLE 75 OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 113
TABLE 76 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 77 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 78 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 79 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 80 OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2022–2029 (USD MILLION) 115
TABLE 81 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 82 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 83 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 84 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 85 OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION) 117
TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 87 EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 90 OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 91 NORTH AMERICA: KEY MACROINDICATORS 122
TABLE 92 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 124
TABLE 94 NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY STAGE, 2022–2029 (USD MILLION) 124
TABLE 95 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 125
TABLE 96 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 125
TABLE 97 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 125
TABLE 98 US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 126
TABLE 99 US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE,
2022–2029 (USD MILLION) 127
TABLE 100 US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 127
TABLE 101 US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 127
TABLE 102 US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 128
TABLE 103 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 129
TABLE 104 CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 129
TABLE 105 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 129
TABLE 106 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 130
TABLE 107 CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 130
TABLE 108 EUROPE: KEY MACROINDICATORS 131
TABLE 109 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 110 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 132
TABLE 111 EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 132
TABLE 112 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 132
TABLE 113 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 133
TABLE 114 EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 133
TABLE 115 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 134
TABLE 116 GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 134
TABLE 117 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 135
TABLE 118 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 135
TABLE 119 GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 135
TABLE 120 UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 136
TABLE 121 UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE,
2022–2029 (USD MILLION) 137
TABLE 122 UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 137
TABLE 123 UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 137
TABLE 124 UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 138
TABLE 125 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 139
TABLE 126 FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 139
TABLE 127 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 139
TABLE 128 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 140
TABLE 129 FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 140
TABLE 130 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 141
TABLE 131 ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 141
TABLE 132 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 141
TABLE 133 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 134 ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 142
TABLE 135 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 143
TABLE 136 SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 143
TABLE 137 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 143
TABLE 138 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 144
TABLE 139 SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 144
TABLE 140 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 145
TABLE 141 REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY STAGE, 2022–2029 (USD MILLION) 145
TABLE 142 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 145
TABLE 143 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 146
TABLE 144 REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 146
TABLE 145 ASIA PACIFIC: KEY MACROINDICATORS 147
TABLE 146 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 147 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 149
TABLE 148 ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY STAGE, 2022–2029 (USD MILLION) 149
TABLE 149 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 150
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 150
TABLE 151 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 150
TABLE 152 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 152
TABLE 153 CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 152
TABLE 154 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 152
TABLE 155 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 156 CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 153
TABLE 157 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 154
TABLE 158 JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 154
TABLE 159 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 154
TABLE 160 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 155
TABLE 161 JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 155
TABLE 162 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 156
TABLE 163 INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 156
TABLE 164 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 157
TABLE 165 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 166 INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 157
TABLE 167 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 158
TABLE 168 SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY STAGE, 2022–2029 (USD MILLION) 158
TABLE 169 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 159
TABLE 170 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 159
TABLE 171 SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 159
TABLE 172 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 161
TABLE 173 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 161
TABLE 174 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 161
TABLE 175 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 162
TABLE 176 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 162
TABLE 177 LATIN AMERICA: KEY MACROINDICATORS 163
TABLE 178 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 163
TABLE 179 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 164
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET,
BY STAGE, 2022–2029 (USD MILLION) 164
TABLE 181 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 164
TABLE 182 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 183 LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 165
TABLE 184 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 166
TABLE 185 BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 166
TABLE 186 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 166
TABLE 187 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 188 BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 167
TABLE 189 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 168
TABLE 190 MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 168
TABLE 191 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 168
TABLE 192 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 193 MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER,
2022–2029 (USD MILLION) 169
TABLE 194 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 170
TABLE 195 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 170
TABLE 196 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 170
TABLE 197 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 171
TABLE 198 REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022–2029 (USD MILLION) 171
TABLE 199 MIDDLE EAST: KEY MACROINDICATORS 172
TABLE 200 AFRICA: KEY MACROINDICATORS 173
TABLE 201 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 173
TABLE 202 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE, 2022–2029 (USD MILLION) 173
TABLE 203 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 174
TABLE 204 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE,
2022–2029 (USD MILLION) 174
TABLE 205 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2022–2029 (USD MILLION) 174
TABLE 206 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS DEPLOYED BY KEY CDMOS, JANUARY 2021–DECEMBER 2024 176
TABLE 207 OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION 179
TABLE 208 OLIGONUCLEOTIDE CDMO MARKET: REGION FOOTPRINT 183
TABLE 209 OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT 184
TABLE 210 OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT 185
TABLE 211 OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT 186
TABLE 212 OLIGONUCLEOTIDE CDMO MARKET: DETAILED LIST OF KEY STARTUP/SMES 189
TABLE 213 OLIGONUCLEOTIDE CDMO MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 190
TABLE 214 OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 193
TABLE 215 OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS,
JANUARY 2021–NOVEMBER 2024 194
TABLE 216 BACHEM: COMPANY OVERVIEW 196
TABLE 217 BACHEM: SERVICES OFFERED 197
TABLE 218 BACHEM: DEALS, JANUARY 2021–DECEMBER 2024 198
TABLE 219 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 199
TABLE 220 THERMO FISHER SCIENTIFIC: SERVICES OFFERED 200
TABLE 221 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–DECEMBER 2024 201
TABLE 222 THERMO FISHER SCIENTIFIC: EXPANSIONS, JANUARY 2021–DECEMBER 2024 201
TABLE 223 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 203
TABLE 224 AGILENT TECHNOLOGIES: SERVICES OFFERED 204
TABLE 225 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021–DECEMBER 2024 205
TABLE 226 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2021–DECEMBER 2024 205
TABLE 227 WUXI APPTEC: COMPANY OVERVIEW 207
TABLE 228 WUXI APPTEC: SERVICES OFFERED 208
TABLE 229 WUXI APPTEC: EXPANSIONS, JANUARY 2021–DECEMBER 2024 209
TABLE 230 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 211
TABLE 231 MARAVAI LIFESCIENCES: SERVICES OFFERED 212
TABLE 232 MARAVAI LIFESCIENCES: DEALS, JANUARY 2021–DECEMBER 2024 213
TABLE 233 LONZA: COMPANY OVERVIEW 214
TABLE 234 LONZA: SERVICES OFFERED 215
TABLE 235 LONZA: DEALS, JANUARY 2021–DECEMBER 2024 216
TABLE 236 LONZA: EXPANSIONS, JANUARY 2021–DECEMBER 2024 216
TABLE 237 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 217
TABLE 238 EUROFINS SCIENTIFIC: SERVICES OFFERED 218
TABLE 239 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–DECEMBER 2024 219
TABLE 240 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–DECEMBER 2024 219
TABLE 241 DANAHER CORPORATION: COMPANY OVERVIEW 220
TABLE 242 DANAHER CORPORATION: SERVICES OFFERED 222
TABLE 243 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 222
TABLE 244 GENSCRIPT: COMPANY OVERVIEW 223
TABLE 245 GENSCRIPT: SERVICES OFFERED 224
TABLE 246 GENSCRIPT: EXPANSIONS, JANUARY 2021–DECEMBER 2024 225
TABLE 247 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 226
TABLE 248 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED 227
TABLE 249 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS,
JANUARY 2021–DECEMBER 2024 227
TABLE 250 EUROAPI: COMPANY OVERVIEW 228
TABLE 251 EUROAPI: SERVICE OFFERED 229
TABLE 252 EUROAPI: DEALS, JANUARY 2021–DECEMBER 2024 230
TABLE 253 EUROAPI: EXPANSIONS, JANUARY 2021–DECEMBER 2024 230
TABLE 254 AJINOMOTO: COMPANY OVERVIEW 231
TABLE 255 AJINOMOTO: SERVICES OFFERED 232
TABLE 256 ST PHARM: COMPANY OVERVIEW 233
TABLE 257 ST PHARM: SERVICES OFFERED 234
TABLE 258 ST PHARM: EXPANSIONS, JANUARY 2021–DECEMBER 2024 234
TABLE 259 ST PHARM: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 234
TABLE 260 KANEKA CORPORATION: COMPANY OVERVIEW 235
TABLE 261 KANEKA CORPORATION: SERVICES OFFERED 236
TABLE 262 POLYPEPTIDE GROUP: COMPANY OVERVIEW 237
TABLE 263 POLYPEPTIDE GROUP: SERVICES OFFERED 238
TABLE 264 POLYPEPTIDE GROUP: DEALS, JANUARY 2021–DECEMBER 2024 239
TABLE 265 AURIGENE PHARMACEUTICAL SERVICES: COMPANY OVERVIEW 240
TABLE 266 AURIGENE PHARMACEUTICAL SERVICES: SERVICES OFFERED 240
TABLE 267 BIOSPRING: COMPANY OVERVIEW 241
TABLE 268 BIOSPRING: SERVICES OFFERED 241
TABLE 269 BIOSPRING: SERVICE APPROVALS, JANUARY 2021–DECEMBER 2024 242
TABLE 270 BIOSPRING: EXPANSIONS, JANUARY 2021–DECEMBER 2024 242
LIST OF FIGURES
FIGURE 1 OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION 28
FIGURE 2 RESEARCH DESIGN 31
FIGURE 3 BREAKDOWN OF PRIMARIES: OLIGONUCLEOTIDE CDMO MARKET 33
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 34
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 35
FIGURE 6 ILLUSTRATIVE EXAMPLE OF BACHEM: REVENUE SHARE ANALYSIS, 2023 35
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 37
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
FIGURE 9 OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 40
FIGURE 11 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE,
2024 VS. 2029 (USD MILLION) 43
FIGURE 12 OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY STAGE,
2024 VS. 2029 (USD MILLION) 44
FIGURE 13 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 44
FIGURE 14 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 45
FIGURE 15 OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 45
FIGURE 16 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC SNAPSHOT 46
FIGURE 17 GROWING FOCUS ON DEVELOPMENT AND COMMERCIALIZATION OF OLIGO-BASED THERAPEUTICS—A KEY FACTOR DRIVING GROWTH 47
FIGURE 18 CONTRACT MANUFACTURING ACCOUNTED FOR LARGEST SHARE
OF NORTH AMERICAN OLIGONUCLEOTIDE CDMO MARKET IN 2023 48
FIGURE 19 ANTISENSE OLIGONUCLEOTIDES SEGMENT TO DOMINATE MARKET TILL 2029 48
FIGURE 20 THERAPEUTIC APPLICATIONS TO HOLD LARGEST MARKET SHARE
THROUGHOUT FORECAST PERIOD 49
FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES HELD LARGEST SHARE OF END-USER MARKET IN 2023 49
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50
FIGURE 23 OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 51
FIGURE 24 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE CDMOS 57
FIGURE 25 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED
BY PROMINENT COMPANIES 58
FIGURE 26 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING
MANUFACTURING PHASE 59
FIGURE 27 OLIGONUCLEOTIDE CDMO SERVICES MARKET ECOSYSTEM 60
FIGURE 28 OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES ANALYSIS 72
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES (PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES) 74
FIGURE 30 BUYING CRITERIA OF END USERS 75
FIGURE 31 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET 78
FIGURE 32 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT 123
FIGURE 33 ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT 148
FIGURE 34 OLIGONUCLEOTIDE CDMO MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2021–2023 (USD MILLION) 177
FIGURE 35 OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 178
FIGURE 36 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 181
FIGURE 37 OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT 182
FIGURE 38 OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 188
FIGURE 39 OLIGONUCLEOTIDE CDMO MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 191
FIGURE 40 OLIGONUCLEOTIDE CDMO MARKET: EV/EBITDA OF KEY VENDORS, 2024 191
FIGURE 41 OLIGONUCLEOTIDE CDMO MARKET: BRAND/SERVICE COMPARISON MATRIX 192
FIGURE 42 BACHEM: COMPANY SNAPSHOT (2023) 197
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2023) 200
FIGURE 44 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2023) 204
FIGURE 45 WUXI APPTEC: COMPANY SNAPSHOT (2023) 208
FIGURE 46 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2023) 212
FIGURE 47 LONZA: COMPANY SNAPSHOT (2023) 215
FIGURE 48 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023) 218
FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 221
FIGURE 50 GENSCRIPT: COMPANY SNAPSHOT (2023) 224
FIGURE 51 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023) 226
FIGURE 52 EUROAPI: COMPANY SNAPSHOT (2023) 229
FIGURE 53 AJINOMOTO: COMPANY SNAPSHOT (2023) 231
FIGURE 54 ST PHARM: COMPANY SNAPSHOT (2023) 233
FIGURE 55 KANEKA CORPORATION: COMPANY SNAPSHOT (2023) 236
FIGURE 56 POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2023) 238
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11